Aptar Pharma and COVIRIX Medical Partner to Develop Inhalable Antiviral Treatments
The collaboration between Aptar Pharma and COVIRIX Medical Partner will focus on a feasibility study to adapt Aptar Pharma’s proprietary Dry Powder Inhalation (DPI) platform for the delivery of COVIRIX Medical’s anti-viral compound.
Nanopharm | 16/03/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy